Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 3/20 | 0.59 |
| ▸ | LCK | P06239 | 4/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.39 |
| ▸ | PRKAA2 | P54646 | 4/20 | 0.39 |
| ▸ | ROS1 | P08922 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.37 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 2/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5996482 | 0.90 | SRC (0.51) | SRCLCKMAPK14KDRPRKAA2 | |
| SCHEMBL5997660 | 0.84 | LCK (0.55) | SRCLCKMAPK14DYRK2PRKAA2 | |
| SCHEMBL2492366 | 0.83 | BTK (0.61) | SRCLCKMAPK14KDRBTK | |
| SCHEMBL5998458 | 0.79 | MAPK14 (0.56) | SRCLCKMAPK14KDRPPARG | |
| SCHEMBL5998110 | 0.79 | P4HTM (0.48) | BTK | |
| SCHEMBL2497163 | 0.78 | SRC (0.50) | SRCDYRK2PRKAA2EGFRALDH1A1 | |
| SCHEMBL12190318 | 0.76 | BTK (0.61) | SRCLCKMAPK14KDRBTK | |
| SCHEMBL5997190 | 0.76 | SRC (0.56) | SRCLCKKDREGFRKDM4E | |
| SCHEMBL5997842 | 0.76 | KDR (0.52) | SRCLCKMAPK14KDR | |
| SCHEMBL5996051 | 0.76 | ABL1 (0.55) | SRCLCKMAPK14KDRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101155799-A | Pyrimidine inhibitors of kinases | TARGEGEN INC (US) | 2008-04-02 | — | — | CN | disclosed |
| US-20060247250-A1 | Pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247250-A1 | Pyrimidine inhibitors of kinases | DTYMK, SRC, DCK | SRC 2/4885LCK 4/4885MAPK14 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.